Cargando…

Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus

Mucus is the first biological component inhaled drugs encounter on their journey towards their pharmacological target in the upper airways. Yet, how mucus may influence drug disposition and efficacy in the lungs has been essentially overlooked. In this study, a simple in vitro system was developed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Alqahtani, Safar, Roberts, Clive J., Stolnik, Snjezana, Bosquillon, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076363/
https://www.ncbi.nlm.nih.gov/pubmed/32053877
http://dx.doi.org/10.3390/pharmaceutics12020145
_version_ 1783507199251709952
author Alqahtani, Safar
Roberts, Clive J.
Stolnik, Snjezana
Bosquillon, Cynthia
author_facet Alqahtani, Safar
Roberts, Clive J.
Stolnik, Snjezana
Bosquillon, Cynthia
author_sort Alqahtani, Safar
collection PubMed
description Mucus is the first biological component inhaled drugs encounter on their journey towards their pharmacological target in the upper airways. Yet, how mucus may influence drug disposition and efficacy in the lungs has been essentially overlooked. In this study, a simple in vitro system was developed to investigate the factors promoting drug interactions with airway mucus in physiologically relevant conditions. Thin layers of porcine tracheal mucus were prepared in Transwell(®) inserts and initially, the diffusion of various fluorescent dyes across those layers was monitored over time. A deposition system featuring a MicroSprayer(®) aerosolizer was optimized to reproducibly deliver liquid aerosols to multiple air-facing layers and then exploited to compare the impact of airway mucus on the transport of inhaled bronchodilators. Both the dyes and drugs tested were distinctly hindered by mucus with high logP compounds being the most affected. The diffusion rate of the bronchodilators across the layers was in the order: ipratropium ≈ glycopyronnium > formoterol > salbutamol > indacaterol, suggesting hydrophobicity plays an important role in their binding to mucus but is not the unique parameter involved. Testing of larger series of compounds would nevertheless be necessary to better understand the interactions of inhaled drugs with airway mucus.
format Online
Article
Text
id pubmed-7076363
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70763632020-03-24 Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus Alqahtani, Safar Roberts, Clive J. Stolnik, Snjezana Bosquillon, Cynthia Pharmaceutics Article Mucus is the first biological component inhaled drugs encounter on their journey towards their pharmacological target in the upper airways. Yet, how mucus may influence drug disposition and efficacy in the lungs has been essentially overlooked. In this study, a simple in vitro system was developed to investigate the factors promoting drug interactions with airway mucus in physiologically relevant conditions. Thin layers of porcine tracheal mucus were prepared in Transwell(®) inserts and initially, the diffusion of various fluorescent dyes across those layers was monitored over time. A deposition system featuring a MicroSprayer(®) aerosolizer was optimized to reproducibly deliver liquid aerosols to multiple air-facing layers and then exploited to compare the impact of airway mucus on the transport of inhaled bronchodilators. Both the dyes and drugs tested were distinctly hindered by mucus with high logP compounds being the most affected. The diffusion rate of the bronchodilators across the layers was in the order: ipratropium ≈ glycopyronnium > formoterol > salbutamol > indacaterol, suggesting hydrophobicity plays an important role in their binding to mucus but is not the unique parameter involved. Testing of larger series of compounds would nevertheless be necessary to better understand the interactions of inhaled drugs with airway mucus. MDPI 2020-02-11 /pmc/articles/PMC7076363/ /pubmed/32053877 http://dx.doi.org/10.3390/pharmaceutics12020145 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alqahtani, Safar
Roberts, Clive J.
Stolnik, Snjezana
Bosquillon, Cynthia
Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus
title Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus
title_full Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus
title_fullStr Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus
title_full_unstemmed Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus
title_short Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus
title_sort development of an in vitro system to study the interactions of aerosolized drugs with pulmonary mucus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076363/
https://www.ncbi.nlm.nih.gov/pubmed/32053877
http://dx.doi.org/10.3390/pharmaceutics12020145
work_keys_str_mv AT alqahtanisafar developmentofaninvitrosystemtostudytheinteractionsofaerosolizeddrugswithpulmonarymucus
AT robertsclivej developmentofaninvitrosystemtostudytheinteractionsofaerosolizeddrugswithpulmonarymucus
AT stolniksnjezana developmentofaninvitrosystemtostudytheinteractionsofaerosolizeddrugswithpulmonarymucus
AT bosquilloncynthia developmentofaninvitrosystemtostudytheinteractionsofaerosolizeddrugswithpulmonarymucus